Oruka Therapeutics (NASDAQ:ORKA) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Oruka Therapeutics (NASDAQ:ORKA) from a hold rating to a sell rating in a research report sent to investors on Sunday morning.

A number of other research analysts have also weighed in on ORKA. HC Wainwright cut their target price on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research note on Thursday, November 13th. They issued a “buy” rating and a $45.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 8th. Wedbush reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 12th. Finally, BTIG Research upped their price target on Oruka Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.14.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $27.45 on Friday. The business’s 50-day simple moving average is $23.08 and its 200-day simple moving average is $16.53. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $29.98. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -9.77 and a beta of -0.30.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. As a group, equities research analysts forecast that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Institutional Trading of Oruka Therapeutics

Hedge funds have recently modified their holdings of the company. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $28,000. Ameritas Investment Partners Inc. bought a new position in Oruka Therapeutics in the second quarter worth $31,000. BNP Paribas Financial Markets boosted its stake in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares in the last quarter. PNC Financial Services Group Inc. bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $39,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $43,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.